Sonya Miller, MBBS, FFARCS, FANZCA, TauRx Therapeutics Ltd., Aberdeen, UK, discusses the promise of tau aggregation inhibitors as a therapeutic strategy in Alzheimer’s disease (AD) and other neurodegenerative conditions. The group have been researching the tau aggregation inhibitor HMTM (hydromethylthionine mesylate; aka TRx0237) and have just finished four global Phase III clinical trials, three of which focused on AD and one on frontotemporal dementia. The findings after 12 months of HMTM use show an improvement in the brain volume of individuals with mild cognitive impairment (MCI) and a reduction in the expected decline in the mild to moderate AD group, versus controls. The group are also undertaking work in Parkinson’s disease, chronic traumatic encephalopathy, and traumatic brain injury. This interview took place at the Alzheimer’s Association International Conference® (AAIC) 2023 in Amsterdam, Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
